Business Context and Reporting Period
This Form 8-K is filed by Aziyo Biologics, Inc. (not Elutia Inc.) on December 13, 2022. The registrant is a Delaware corporation trading on the Nasdaq Capital Market under the symbol AZYO. The report details a specific financing event rather than providing comprehensive periodic financial results.
Key Financial Metrics
The filing focuses on debt obligations and liquidity events:
- New Borrowing: The Company drew an additional term loan of $4.0 million on December 13, 2022.
- Total Borrowings: Following this draw, total borrowings under the Credit Agreement reached $25.0 million.
- Debt Composition:
- Initial Term Loan: $21.0 million (funded August 10, 2022).
- Subsequent Term Loan: $4.0 million.
- Accrued Interest (Paid-in-Kind): Approximately $0.3 million.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or margins.
Material Changes
The primary material change is the increase in the Company's direct financial obligation. The total principal balance under the Credit Agreement increased by $4.0 million due to the election to draw the Subsequent Term Loan. Additionally, approximately $0.3 million of accrued interest from the initial term loan was capitalized (paid in kind), further increasing the outstanding principal balance.
Outlook, Risks, and Management Commentary
The filing references the Credit Agreement dated August 10, 2022, and subsequent amendments. Material terms are incorporated by reference from prior 8-K filings (August 15, November 28, and December 5, 2022). The Company is identified as an emerging growth company. No specific forward-looking guidance, risk factors, or unusual items are detailed within this specific text excerpt beyond the execution of the loan draw.
Investor Verification Checklist
- Verify the total outstanding debt balance of $25.0 million against the most recent 10-Q or 10-K.
- Review the full Credit Agreement terms (interest rates, maturity, covenants) referenced in prior 8-K filings.
- Confirm the impact of the $0.3 million paid-in-kind interest on future interest expense calculations.
- Check for any subsequent filings regarding the utilization of the $4.0 million proceeds.